Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
FEMY vs BLFS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
BLFS Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–1 Matrix Metrics)
BLFS Overall Winner
6-Pillar Tally: FEMY 0 – 6 BLFS
Matrix Metrics: FEMY 1 – 9 BLFS
As of Nov 16, 2026, BioLife Solutions Inc. (BLFS) is the stronger overall head-to-head candidate over Femasys Inc. (FEMY) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). FEMY carries a Unified Composite Score of 52.6/100 (HOLD) at $1.28 (N/M Forward P/E, -763.9% operating margin), whereas BLFS carries 46.0/100 (HOLD) at $38.61 (117.0x Forward P/E, 6.0% operating margin).
- Composite vs. Pillar Nuance: While FEMY currently prints a higher short-term Unified Composite Score (52.6/100 HOLD vs. BLFS 46.0/100 HOLD), BLFS captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (6.0% vs. -763.9% operating margin) and revenue trajectory (+21.5% vs. -18.9% YoY).
- Technical & Structure Timing Caution: FEMY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.6); meanwhile BLFS trades in a Markup technical trend (BREAKOUT options phase, RSI 60.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About FEMY vs BLFS
FEMY
Femasys Inc. Common Stock
$1.28
-9.86% 1D
Market Cap
$11.9M
TTM Revenue
$2.3M
Forward P/E
N/M
Beta / 30D Vol
4.01β · 72% Vol
Unified Composite Score
52.6
HOLD
Tech 61.0
Fund 62.0
Flow 50.0
Mom 64.0
Weinstein Technical Phase
Markdown · Sell / avoid
BLFS
Head-to-Head Winner
BioLife Solutions Inc.
$38.61
+3.51% 1D
Market Cap
$1.8B
TTM Revenue
$107M
Forward P/E
117.0x
Beta / 30D Vol
1.05β · 31% Vol
Unified Composite Score
46.0
HOLD
Tech 27.0
Fund 46.0
Flow 59.0
Mom 56.0
Weinstein Technical Phase
Markup · Hold / add on dips
6-Pillar Scorecard Institutional Category Breakdown (FEMY 0 – 6 BLFS)
1. Valuation Multiples
BLFS
Forward P/E
N/M
117.0x
Trailing P/E
N/M
37.3x
PEG Ratio
N/M
N/M
EV / Revenue
4.9x
17.0x
2. Growth & Scale
BLFS
Revenue Growth (YoY)
-18.9%
+21.5%
Earnings Growth (YoY)
+0.0%
-13.9%
TTM Revenue (USD)
$2.3M
$107M
Market Cap
$11.9M
$1.8B
3. Profitability & Quality
BLFS
Gross Margin
60.9%
63.6%
Operating Margin
-763.9%
6.0%
Net Profit Margin
0.0%
54.4%
Return on Equity (ROE)
-425.0%
12.8%
4. Balance Sheet & Cash Flow
BLFS
Cash Generation (TTM)
-$19M
-$2.2M
Cash Flow Margin
N/A
-2.1%
Net Cash / Leverage
-$658,045 Net Debt (0.65x D/E)
$8.3M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
BLFS
Options Structure Phase
UNCLASSIFIED
BREAKOUT
Current IV / %ile
N/A (N/A)
40.1% (6th %ile)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markdown
ACCUMULATION · Markup
6. R&D & Supply-Chain Moat
BLFS
OpEx & R&D Intensity
N/A
57.6% of Rev ($61M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Instruments & Supplies Operator
Medical Instruments & Supplies Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: FEMY (1) vs BLFS (9)| Institutional Metric | FEMY | BLFS | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $11.9M | $1.8B | BLFS | |
| Trailing P/E Ratio | N/M | 37.3x | BLFS | |
| Forward P/E Ratio | N/M | 117.0x | BLFS | |
| Revenue Growth (YoY) | -18.9% | +21.5% | BLFS | |
| Operating Margin (TTM) | -763.9% | 6.0% | BLFS | |
| Net Profit Margin | 0.0% | 54.4% | BLFS | |
| Return on Equity (ROE) | -425.0% | 12.8% | BLFS | |
| 52-Week Range Position | 17% ($0–$6) | 95% ($18–$40) | BLFS | |
| Beta / 30D Volatility | 4.01β · 72% Vol | 1.05β · 31% Vol | BLFS | |
| Unified Institutional Score | 52.6 / 100 (HOLD) | 46.0 / 100 (HOLD) | FEMY | |
| Trailing 12M Revenue (USD) | $2.3M | $107M | Scale | |
| Gross Profit Margin (TTM) | 60.9% | 63.6% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 4.9x EV/Rev | N/M PEG · 17.0x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$19M (-$658,045 Net Debt (0.65x D/E)) | -$2.2M ($8.3M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
BLFS +42.66 pp
3M Horizon
BLFS +86.04 pp
6M Horizon
FEMY +269.74 pp
1Y Horizon
FEMY +90.68 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | FEMY Revenue | BLFS Revenue | FEMY Op. Margin | BLFS Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | N/A | $20M | N/A | 18.5% | BLFS |
| FY2019 | N/A | $30M | N/A | -0.8% | BLFS |
| FY2020 | $0M | $50M | -668.0% | -13.0% | BLFS |
| FY2021 | $0M | $120M | -706.7% | -29.5% | BLFS |
| FY2022 | $0M | $80M | -961.7% | -7.8% | BLFS |
| FY2023 | $0M | $70M | -1353.4% | -25.3% | BLFS |
| FY2024 | $0M | $70M | -1091.8% | -6.0% | BLFS |
| FY2025 | $0M | $100M | -767.0% | -17.3% | BLFS |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
FEMY
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact FEMY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
BLFS
BREAKOUT
Current IV
40.1%
IV Percentile
6th %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact BLFS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
FEMY Moat Profile
Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
BLFS Moat Profile
Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
OpEx & R&D Reinvestment
57.6% of Rev ($61M)
90D Engineering Disclosures
0 Published
Investor FAQ FEMY vs BLFS Key Questions & Quantitative Answers
As of Nov 16, 2026, BioLife Solutions Inc. (BLFS) is the stronger overall head-to-head candidate over Femasys Inc. (FEMY) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). FEMY carries a Unified Composite Score of 52.6/100 (HOLD) at $1.28 (N/M Forward P/E, -763.9% operating margin), whereas BLFS carries 46.0/100 (HOLD) at $38.61 (117.0x Forward P/E, 6.0% operating margin). Composite vs. Pillar Nuance: While FEMY currently prints a higher short-term Unified Composite Score (52.6/100 HOLD vs. BLFS 46.0/100 HOLD), BLFS captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (6.0% vs. -763.9% operating margin) and revenue trajectory (+21.5% vs. -18.9% YoY). Technical & Structure Timing Caution: FEMY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.6); meanwhile BLFS trades in a Markup technical trend (BREAKOUT options phase, RSI 60.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
BLFS leads the Growth & Scale pillar: FEMY posts -18.9% YoY revenue growth and +0.0% YoY earnings growth on $2.3M TTM revenue (60.9% gross margin, -763.9% operating margin), compared with BLFS at +21.5% YoY revenue growth and -13.9% YoY earnings growth on $107M TTM revenue (63.6% gross margin, 6.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), FEMY cumulative revenue shifted N/A while BLFS shifted +400.0%. In operating R&D and SG&A reinvestment, FEMY deploys N/A (0 90-day corporate R&D disclosures) versus 57.6% of Rev ($61M) (0 disclosures) for BLFS.
BLFS screens cheaper on headline valuation multiples. FEMY trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 4.9x EV/Revenue (unreported FCF margin), whereas BLFS trades at 117.0x Forward P/E, 37.3x Trailing P/E, N/M PEG, and 17.0x EV/Revenue (-2.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FEMY (-425.0% ROE) versus BLFS (12.8% ROE) capital efficiency.
In options market volatility and institutional positioning, FEMY carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.01β · 72% Vol realized risk). By comparison, BLFS carries 40.1% implied volatility (6th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.05β · 31% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
BLFS vs FEMY · Reverse Pair
BLFS vs CYRX
· Sector Peer
BLFS vs AXGN
· Sector Peer
BLFS vs VCEL
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking